The US Drug Watchdog Initiates A National Investigation Of The Diabetes Drug Called Actos & Wants To

The US Drug Watchdog wants to hear from any user of the diabetes drug called Actos, who developed bladder cancer. According to the AP, "The FDA has issued a warning that Actos may be linked to an increased risk of bladder cancer. Meanwhile, both Germany and France have suspended sales of Actos. The Actos suspension is effective July 11, 2011. Actos (pioglitazone), along with another diabetes drug made by Takeda Pharmaceutical, Competact, came under fire in Europe after a study revealed an increased risk for bladder cancer among diabetes patients who were taking the medication." The
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations